GreenLight Biosciences Announces Series D Financing

GreenLight Biosciences, Inc., announced today the completion of its $18 million Series D round of financing, led by Fall Line Capital. S2G Ventures, Lewis and Clark Ventures, and Macro Capital Investments participated in the round.

GreenLight Biosciences has developed a unique cell-free bioprocessing platform capable of producing RNA sequences of exceptional fidelity in a fully-scalable fashion at a fraction of the costs of other technologies. The company is focused on development of dsRNA-based products for crop agriculture, and it is developing additional RNA offerings in the areas of public health, vaccine development and human therapeutics.

“We believe that GreenLight’s proprietary cell-free platform, and its pipeline of RNA-based products targeting significant applications in agriculture, are truly unique in the industry,” said Eric O’Brien, cofounder and managing director of Fall Line Capital.  “Double-stranded RNAs (dsRNA) produced with GreenLight’s cell-free platform have the potential to revolutionize how agricultural pests are addressed and controlled at a global scale, using highly-specific, sustainable approaches.”   

GreenLight plans to use the funds to accelerate development and field testing of a number of dsRNA molecules targeting insect and viral pests in high-value crops. The funds will also be used to expand GreenLight’s team.